Alto Neuroscience, Inc. (ANRO)
NYSE: ANRO · Real-Time Price · USD
14.76
+0.72 (5.13%)
Oct 30, 2025, 11:34 AM EDT - Market open
Alto Neuroscience Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
76
Market Cap
399.65M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 210.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionANRO News
- 2 days ago - Alto Neuroscience to Participate in Upcoming Investor Conferences - Business Wire
- 10 days ago - Alto Neuroscience Announces $50 Million Private Placement Financing - Business Wire
- 10 days ago - Alto Neuroscience Announces Plans to Accelerate Development of ALTO-207 in Treatment Resistant Depression Following Successful Outcome from Recent FDA Meeting - Business Wire
- 22 days ago - Johnson Fistel, PLLP Investigates Claims on Behalf of Alto Neuroscience, Inc. Long-Term Shareholders - GlobeNewsWire
- 27 days ago - Johnson Fistel, PLLP Investigates Claims on Behalf of Alto Neuroscience, Inc. Long-Term Shareholders - GlobeNewsWire
- 27 days ago - Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia - Business Wire
- 6 weeks ago - INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience - PRNewsWire
- 7 weeks ago - Alto Neuroscience Announces Robust Replication of EEG Biomarker to Objectively Identify Patients with Cognitive Impairment in Schizophrenia - Business Wire